MedTrace Logo

Safety and Immunogenicity of Candidate HIV Vaccines Given Sequentially

NCT04563377 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2022-09-01

No results posted yet for this study

Summary

The primary object of the study is to assess the safety profile of candidate vaccines ChAdOx1.HTI and MVA.HTI administered sequentially in healthy HIV-1/2 negative adult volunteers.

In addition, the study will assess the immune responses generated of the candidate vaccines ChAdOx1.HTI and MVA.HTI administered sequentially in healthy HIV-1/2 negative adult volunteers.

10 healthy, HIV-negative adult volunteers will receive one vaccination of CHAdOx1.HTI followed by a one vaccination of MVA.HTI 8 weeks later.

Conditions

  • Healthy

Interventions

BIOLOGICAL

ChAdOx1.HTI and MVA.HTI

ChAdOx1. HTI dose 5 x 10\^10 vp MVA.HTI dose 2 x 10\^8 pfu

Sponsors & Collaborators

  • University of Oxford

    lead OTHER

Principal Investigators

  • Paola Cicconi · Dr Paola Cicconi

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-11-01
Primary Completion
2022-08-16
Completion
2022-08-16

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04563377 on ClinicalTrials.gov